American Society of Hirudotherapy

The Reverse Superficial Sural Artery Flap Revisited for Complex Lower Extremity and Foot Reconstruction

Research article published in Plastic and reconstructive surgery. Global open (2015)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureSugg KB et al. · Plastic and reconstructive surgery. Global open, 2015

Abstract

BACKGROUND: Soft-tissue defects of the distal lower extremity and foot present significant challenges to the reconstructive surgeon. The reverse superficial sural artery flap (RSSAF) is a popular option for many of these difficult wounds. Our initial experience with this flap at multiple institutions resulted in a 50% failure rate, mostly because of critical venous congestion. To overcome this, we have modified our operative technique, which has produced a more reliable flap. METHODS: All patients reconstructed with an RSSAF between May 2002 and September 2013 were retrospectively reviewed. In response to a high rate of venous congestion in an early group of patients, we adopted a uniform change in operative technique for a late group of patients. A key modification was an increase in pedicle width to at least 4 cm. Outcomes of interest included postoperative complications and limb salvage rate. RESULTS: Twenty-seven patients were reconstructed with an RSSAF (n = 12 for early group, n = 15 for late group). Salvage rate in the early group was 50% compared with 93% in the late group (P = 0.02). Postoperative complications (75% vs. 67%, P = 0.70) were similar between groups. Venous congestion that required leech therapy was 42% in the early group (n = 5) and 0% in the late group (P = 0.01). CONCLUSIONS: Venous congestion greatly impairs the survival of the RSSAF. A pedicle width of at least 4 cm is recommended to maintain venous drainage and preserve flap viability.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

In 27 patients reconstructed with reverse superficial sural artery flaps, widening the pedicle to at least 4 cm improved limb salvage from 50% to 93% and eliminated venous congestion requiring leech therapy.

Why This Matters for Hirudotherapy

This retrospective review of 27 patients reconstructed with a reverse superficial sural artery flap compared an early group (pedicle width not standardized) with a late group (pedicle width ≥4 cm), finding improved limb salvage (93% vs. 50%) and elimination of venous congestion requiring leech therapy (0% vs. 42%) in the late group. Leech therapy was used as a clinical intervention for venous congestion in the early cohort, illustrating a real reconstructive surgery application of hirudotherapy. However, the study's primary focus is surgical technique modification; leech therapy is reported only as a complication metric, not evaluated for efficacy or outcomes. No leech secretome biochemistry is addressed.

Citation

Reference (Vancouver style)

Sugg KB, Schaub TA, Concannon MJ, Cederna PS, Brown DL. The Reverse Superficial Sural Artery Flap Revisited for Complex Lower Extremity and Foot Reconstruction. Plast Reconstr Surg Glob Open. 2015;3(9):e519. doi:10.1097/GOX.0000000000000500. PMID: 26495232

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.